San Raffaele Scientific Institute, Division of Regenerative Medicine, Via Olgettina 58, 20132 Milan, Italy.
Pharmacol Res. 2011 Sep;64(3):210-7. doi: 10.1016/j.phrs.2011.05.003. Epub 2011 May 12.
A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have analysed the effects of a derivative of ibuprofen, NCX 320, belonging to the class of cyclooxygenase inhibiting nitric oxide donator (CINOD), in the α-sarcoglycan null mice, a severe mouse model of dystrophy. NCX 320 was administered daily in the diet for 8months starting 1month from weaning. Muscle functional recovery was evaluated by free wheel and treadmill tests at 8months. Serum creatine kinase activity, as well as the number of diaphragm inflammatory infiltrates and necrotic fibres, was measured as indexes of skeletal muscle damage. Muscle regeneration was evaluated in diaphragm and tibialis anterior muscles, measuring the numbers of centronucleated fibres and of myogenic precursor cells. NCX 320 mitigated muscle damage, reducing significantly serum creatine kinase activity, the number of necrotic fibres and inflammatory infiltrates. Moreover, NCX 320 stimulated muscle regeneration increasing significantly the number of myogenic precursor cells and regenerating fibres. All these effects concurred in inducing a significant improvement of muscle function, as assessed by both free wheel and treadmill tests. These results describe the properties of a new compound incorporating nitric oxide donation together with anti-inflammatory properties, showing that it is effective in slowing muscle dystrophy progression long term. Of importance, this new compound deserves specific attention for its potential in the therapy of muscular dystrophy given that ibuprofen is well tolerated in paediatric patients and with a profile of safety that makes it suitable for chronic treatment such as the one required in muscular dystrophies.
目前仍缺乏针对肌肉萎缩症(一组导致肌肉退化、严重时导致死亡的遗传疾病)的有效治疗方法。由于炎症和一氧化氮生成缺陷被认为是肌肉萎缩症的关键致病事件,我们分析了一种布洛芬衍生物 NCX 320 在缺乏α-横纹肌聚糖的小鼠(一种严重的肌肉萎缩症小鼠模型)中的作用。NCX 320 在断奶后 1 个月开始,每日通过饮食给药,持续 8 个月。在 8 个月时,通过自由轮和跑步机测试评估肌肉功能恢复情况。血清肌酸激酶活性以及膈肌炎症浸润和坏死纤维的数量被作为骨骼肌损伤的指标进行测量。通过测量膈肌和比目鱼肌中中心核纤维和肌源性前体细胞的数量来评估肌肉再生情况。NCX 320 减轻了肌肉损伤,显著降低了血清肌酸激酶活性、坏死纤维和炎症浸润的数量。此外,NCX 320 刺激肌肉再生,显著增加了肌源性前体细胞和再生纤维的数量。所有这些作用共同导致肌肉功能的显著改善,通过自由轮和跑步机测试进行评估。这些结果描述了一种新化合物的特性,该化合物结合了一氧化氮供体和抗炎特性,表明它在长期内有效减缓肌肉萎缩症的进展。重要的是,鉴于布洛芬在儿科患者中耐受性良好,并且安全性良好,使其适合慢性治疗,如肌肉萎缩症所需的治疗,这种新化合物值得特别关注,具有治疗肌肉萎缩症的潜力。